Dr. Summit Singhaviranon and Dr. Pramod Srivastava's lab published a paper, entitled Low-avidity T cells drive endogenous tumor immunity in mice and humans in Nature Immunology, which demonstrates the superior anti-tumor activity of T cells with weak binding to cancer cells over T cells with strong binding to cancer cells in both mice and humans. Their paper both provides a fundamental mechanistic rationale for this finding and proposes a viable approach to translate these findings to patient care.  Their work  challenges the existing paradigm that is focused on maximizing T cell binding to cancer cells and has the potential to improve cancer patient outcomes in numerous ways.